top of page

Genmab Website

Find more information about all of Genmab's products on our website at

Genmab Medical Information

Submit a question to Genmab Global Medical Information


DuoBody     Technology Platform


DuoBody    -PD-L1x4-1BB (GEN1046)


MOA Videos

Tisotumab Vedotin

Subcutaneous (SC) Epcoritamab Induces Complete Responses Across R/R B-Cell NHL Subtypes: Updated Dose-Escalation Data

Presentation details:

Sunday, February 21, 2021

Time: 15:30–17:00 JST

Martin Hutchings, MD, PhD

Rigshospitalet, Copenhagen University Hospital
Copenhagen, Denmark

Phase I/IIa Trial Evaluating Safety and Clinical Activity of
DuoBody    -PD-L1×4-1BB (GEN1046) in Advanced Solid Tumors


Presentation details:

Sunday, February 21, 2021

Time: 08:30–09:25 JST

Ignacio Melero, MD

Department of Immunology, Clinica Universidad de Navarra Pamplona, Spain

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer: Phase 2 innovaTV 204 Study Results

Ignace Vergote, MD, PhD

Belgium and Luxembourg Gynaecological Oncology Group, University of Leuven, Leuven Cancer Institute

Leuven, Belgium

Presentation details:

Saturday, February 20, 2021

Time: 15:30–17:35 JST

Japanese Society of Medical Oncology (JSMO)
Virtual Annual Meeting

February 18–21, 2021

Online materials available until March 31, 2021

© 2021 Genmab A/S

bottom of page